CD8A and liver cancer: reported that anti‐CD4‐anti‐PD1 treatment did not reduce the incidence of liver cancer and the non‐alcoholic fatty liver disease activity score in non‐alcoholic steatohepatits mouse model while anti‐CD8‐anti‐PD1 and anti‐TNF‐anti‐PD1 antibodies ameliorated liver damage, liver pathology, and liver inflammation.